Solutions

Clinical Insights: August 10, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Izervay™ (avacincaptad pegol) Intravitreal Solution – New Drug Approval – August 5, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), announced the U.S. Food…

Read More...

Clinical Insights: June 14, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Linzess® (linaclotide) Capsules – New Label Expansion – June 12, 2023 – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today…

Read More...

Clinical Insights: June 7, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Abrysvo™ (respiratory syncytial virus vaccine) Injection – New Drug Approval – May 31, 2023 – Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has…

Read More...

Clinical Insights: May 24, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Opvee® (nalmefene hydrochloride) Nasal Spray – New Drug Approval – May 22, 2023 – The U.S. Food and Drug Administration approved Opvee®, the first nalmefene hydrochloride nasal spray for the…

Read More...

Clinical Insights: May 17, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Veozah™ (fezolinetant) – New Drug Approval – May 12, 2023 – The U.S. Food and Drug Administration approved Veozah™ (fezolinetant), an oral medication for the treatment of moderate to…

Read More...

Clinical Insights: May 3, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Lumryz™ (sodium oxybate) – formerly FT218 – New Drug Approval – May 1, 2023 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform…

Read More...

Clinical Insights: April 26, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Polivy® (polatuzumab vedotin-piiq) – New Label Expansion ­– April 19, 2023 – The Food and Drug Administration approved polatuzumab vedotin-piiq (Polivy®, Genentech, Inc.)…

Read More...

Clinical Insights: April 19, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Omisirge® (omidubicel-onlv) Suspension for Infusion – New Drug Approval – April 17, 2023 – The U.S. Food and Drug Administration approved Omisirge® (omidubicel-onlv), a substantially modified allogeneic (donor) cord…

Read More...

Clinical Insights: April 12, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage April 10, 2023 Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets (Currently in Shortage) April 06,…

Read More...

Clinical Insights: March 22, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Tafinlar® (dabrafenib) – New Label Expansion – March 16, 2023 – The Food and Drug Administration approved dabrafenib (Tafinlar®, Novartis) with trametinib (Mekinist®,…

Read More...

Clinical Insights: February 22, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Filspari™ (sparsentan) Tablets – New Drug Approval – February 17, 2023 – Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to…

Read More...

Clinical Insights: February 15, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval  Takhzyro® (lanadelumab-flyo) – New Expanded Label – February 3, 2023 – Takeda announced that the U.S. Food and Drug Administration (FDA) has approved…

Read More...